“WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off” — what this page in the network covers. WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.3 per cent increase in profit as it secures more projects across the drug development value chain, from discovery through to manufacturing. In a positive profit alert filed with the Hong Kong stock exchange on Wedne Nova Global News curates publicly available headlines and summaries with source attribution.
Third-party article rights, trademarks, images, and publisher names belong to their respective owners; read the original article at the source for full context. Part of the Nova Ecosystem — the platform where AI apps, news, and tools are built and deployed. The full version stays on the original page, which this listing opens directly.